Mel treatments have also been associated with lower enzymatic activities of SOD and CAT accompanied by an increased level of ROS observed in human colorectal cancer cells and in the hepatocellular carcinoma cells [53], [52]. The gene discussed is SOD1; the disease is hepatocellular carcinoma.